Mabion S.A.
Major Drugs - Konstantynów Łódzki, N/A, PL
Mabion S.A. Employees
Paulina Konderak
Specjalista ds. ochrony środowiska. Koordynator ds. ZSZ. Starszy Inspektor ds. BHP
Mabion S.A. Details
Mabion S.A. (WSE: MAB), is Polish biopharmaceutical company established in 2007 with its core competency being the development of latest generation pharmaceuticals based on recombinant proteins technologies (e.g. monoclonal antibodies). Mabion's capabilities begin with the drug design phase, including selection of both upstream and downstreamtechnologies, up through GMP manufacturing operations (DS and DP), as well as development of analytical tools (structural, functional, physicochemical), clinical development, clinical analytics (PK, PD, NAB, ADA) and full regulatory coverage of all development and operational activities. The company's most advanced project is MabionCD20, a biosimilar to MabThera (Rituximab) with the therapeutic indications fornon-Hodgkin's lymphoma, Leukemia and Rheumatoid Arthritis (RA). Currently, MabionCD20 is in an advanced clinical stage. Since signing a contract with Novavax in October 2021 for the commercial production of a COVID-19 vaccine, Mabion has been developing and extending its existing platform to CDMO activities, namely contract development, GMP manufacturing services, and GMP/GLP analytical services in the full scope of the capabilities mentioned above. Mabion has been listed on the Warsaw Stock Exchange since 2013.
Mabion S.A. Technologies
Email Providers
Outlook
Widgets
Google Play
CMS
WordPress.org
Other
Mobile Friendly
Analytics and Tracking
Google Analytics
CSS and JavaScript Libraries
Bootstrap Framework